inucimab
Phase 2- Indications
- Metabolic diseases
Company intelligence / Profile preview
Zhongshan Kangfang Biomedical
Zhongshan, Guangdong Sheng, Chinaakesobio.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Akeso has developed one of China's most diversified innovative antibody pipelines with over 50 candidates, including three approved drugs. Its lead product Ivonescimab outperformed Pembrolizumab in a phase 3 head-to-head trial for non-small cell lung cancer and was approved in China in May 2024. The company has multiple late-stage clinical trials ongoing.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugatemRNA-based drugsCell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Summit TherapeuticsGE HealthcareChina Biopharmaceuticals
Beyond the preview
Go deeper on Zhongshan Kangfang Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhongshan Kangfang Biomedical.